NL-OMON35318已完成3 期
A 2x2 Factorial, Randomized, Multicenter, Single-Blind Evaluation of Intracoronary Abciximab Infusion and Aspiration Thrombectomy in Patients Undergoing Percutaneous Coronary Intervention for Anterior ST-Segment Elevation Myocardial Infarction - INFUSE AMI
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 50
研究概览
简要总结
Trial is onging in other countries
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •- >= 18 years of age;
- •- Anterior MI with ECG showing at least 1 mm of ST-segment elevation in 2 or more contiguous leads in V1-V4, or new (or presumably new) left bundle branch block;
- •- Anticipated symptom onset to balloon or aspiration time of <= 5 hours;
- •- Infarct artery located in the proximal or mid left anterior descending coronary artery, with TIMI 0, 1 or 2 flow at the time of initial diagnostic angiography (prior to wire passage);
- •- Based on coronary anatomy, PCI is indicated for revascularization;
- •- Only one epicardial coronary artery will be treated;
- •- Expected ability to deliver a ClearWay* RX Infusion Catheter to the infarct lesion (absence of excessive tortuosity, diffuse disease or moderate/heavy calcification).
排除标准
- •- Prior myocardial infarction, or known prior systolic dysfunction (known ejection fraction <40% by any prior measure or regional wall motion abnormalities);
- •- An elective surgical procedure is planned that would necessitate interruption of anti-platelet agents during the first twelve months post enrollment;
- •- Subjects who previously underwent coronary stent implantation and in whom coronary angiography demonstrates stent thrombosis to be the cause of the AMI;
- •- Subject has previously undergone an angioplasty or stenting procedure in the left anterior descending artery;
- •- Any contraindication to undergo MRI imaging.
- •- Coronary anatomy such that coronary artery bypass graft surgery will possibly be required within 30 days;
- •- Multivessel intervention required during the index procedure
- •- Severe vessel tortuosity, diffuse disease or severe calcification is present which may impede successful delivery of the Clearway Catheter
- •- Subjects who have prior history of bypass surgery (CABG);
- •- MI is due to thrombosis within or adjacent to a previously implanted stent;
- •- Left ventriculography demonstrates severe mitral regurgitation or a VSD;
- •- Unprotected left main stenosis >40% or that will require intervention;
- •- Subject has received >5000 units of unfractionated heparin within the preceding 24 hours prior to presenting to the catheterization laboratory, or any subject who receives heparin after arrival in the cardiac catheterization laboratory prior to randomization.
研究者
相似试验
已完成
2 期
A Phase 2, Multi-Center, Double-Blind, Randomized, Dose-Ranging, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability Of CK-2127107 In Patients with Amyotrophic Lateral Sclerosis (ALS)Motor Neuron DiseaseAmyotrophic Lateral Sclerosism (ALS)10029317NL-OMON45879Cytokinetics, Inc.11
已完成
2 期
A Phase 2, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 in Patients With Heterozygous Familial HypercholesterolemiaHeterozygous Familial HypercholesterolemiaNL-OMON45499Madrigal Pharmaceuticals, Inc.24
已完成
2 期
A Phase 2, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Study of LY3074828 in Subjects with Moderate to Severe Ulcerative Colitisinflamatory bowel disease10017969Ulcerative colitisNL-OMON46940Eli Lilly and Company7
已完成
2 期
A Phase 2b Multicentre, Randomised, Double-Blind, Active Controlled, Parallel Group Dose-Ranging Study to Assess the Efficacy, Safety and Tolerability of Zibotentan and Dapagliflozin in Patients with Chronic Kidney Disease with Estimated Glomerular Filtration Rate (eGFR) Between 20 and 60 mL/min/1.73 m2Chronic Kidney DiseaseNL-OMON52170Astra Zeneca9
已完成
3 期
A prospective, multicenter, randomised, double-blind, placebo-controlled, parallel groups, phase 2/3 study to compare the efficacy and safety of masitinib versus placebo in the treatment of patients suffering from Amyotrophic Lateral Sclerosis (ALS)ALSAmyotrophic Lateral Sclerosis10011305NL-OMON44970AB Science10